SMHS MethodsHeterogeneity MetaAnalysis

Methods for Studying Heterogeneity of Treatment Effects, Case-Studies of Comparative Effectiveness Research - Meta-Analyses

Overview

Meta-analysis is an approach to combine treatment effects across trials or studies into an aggregated treatment effect with higher statistical power than observed in each individual trials. It may detect HTE by testing for differences in treatment effects across similar RCTs. It requires that the individual treatment effects are similar to ensure pooling is meaningful. In the presence of large clinical or methodological differences between the trials, it may be to avoid meta-analyses. The presence of HTE across studies in a meta-analysis may be due to differences in the design or execution of the individual trials (e.g., randomization methods, patient selection criteria). Cochran's Q is a methods for detection of heterogeneity, which is computed as the weighted sum of squared differences between each study's treatment effect and the pooled effects across the studies. It is a barometer of inter-trial differences impacting the observed study result. A possible source of error in a meta-analysis is publication bias. Trial size may introduce publication bias since larger trials are more likely to be published. Language and accessibility represent other potential confounding factors. When the heterogeneity is not due to poor study design, it may be useful to optimize the treatment benefits for different cohorts of participants.

Cochran's Q statistics is the weighted sum of squares on a standardized scale. The corresponding P value indicates the strength of the evidence of presence of heterogeneity. This test may have low power to detect heterogeneity sometimes and it is suggested to use a value of 0.10 as a cut-off for significance (Higgins et al., 2003). The Q statistics also may have too much power as a test of heterogeneity when the number of studies is large.

Simulation Example 1

# Install and Load library
install.packages("meta")
library(meta)

# Set number of studies
n.studies = 15

# number of treatments: case1, case2, control
n.trt = 3

# number of outcomes
n.event = 2

# simulate the (balanced) number of cases (case1 and case2) and controls in each study
ctl.group = rbinom(n = n.studies, size = 200, prob = 0.3)
case1.group = rbinom(n = n.studies, size = 200, prob = 0.3)
case2.group = rbinom(n = n.studies, size = 200, prob = 0.3)

# Simulate the number of outcome events (e.g., deaths) and no events in the control group
event.ctl.group = rbinom(n = n.studies, size = ctl.group, prob = rep(0.1, length(ctl.group)))
noevent.ctl.group = ctl.group - event.ctl.group

# Simulate the number of events and no events in the case1 group
event.case1.group = rbinom(n = n.studies, size = case1.group, prob = rep(0.5, length(case1.group)))
noevent.case1.group = case1.group - event.case1.group

# Simulate the number of events and no events in the case2 group
event.case2.group = rbinom(n = n.studies, size = case2.group, prob = rep(0.6, length(case2.group)))
noevent.case2.group = case2.group - event.case2.group

# Run the univariate meta-analysis using metabin(), Meta-analysis of binary outcome data – 
# Calculation of fixed and random effects estimates (risk ratio, odds ratio, risk difference or arcsine
# difference) for meta-analyses with binary outcome data.   Mantel-Haenszel (MH), 
#  inverse variance and Peto method are available for pooling.

# method = A character string indicating which method is to be used for pooling of studies. 
# one of "MH" , "Inverse" , or "Cochran"
# sm = A character string indicating which summary measure (“OR”, "RR" "RD"=risk difference) is to be 
# used for pooling of studies

# Control vs. Case1, n.e and n.c are numbers in experimental and control groups
meta.ctr_case1 <- metabin(event.e = event.case1.group, n.e = case1.group, event.c = event.ctl.group, 
n.c = ctl.group, method = "MH", sm = "OR")
# in this case we use Odds Ratio, of the odds of death in the experimental and control studies
forest(meta.ctr_case1)

# Control vs. Case2
meta.ctr_case2 <- metabin(event.e = event.case2.group, n.e = case2.group, event.c = event.ctl.group, 
n.c = ctl.group, method = "MH", sm = "OR")
forest(meta.ctr_case2)

# Case1 vs. Case2
meta.case1_case2 <- metabin(event.e = event.case1.group, n.e = case1.group, event.c = event.case2.group, 
n.c = case2.group, method = "MH", sm = "OR")
forest(meta.case1_case2)
summary(meta.case1_case2)

Test of heterogeneity:
    Q 	d.f.  	p-value
11.99   	14   	0.6071

The forest plot shows the I2 test indicates the evidence to reject the null hypothesis (no study heterogeneity and the fixed effects model should be used).

Series of “N of 1” trials

This technique combines (a “series of”) n-of-1 trial data to identify HTE. An n-of-1 trial is a repeated crossover trial for a single patient, which randomly assigns the patient to one treatment vs. another for a given time period, after which the patient is re-randomized to treatment for the next time period, usually repeated for 4-6 time periods. Such trials are most feasibly done in chronic conditions, where little or no washout period is needed between treatments and treatment effects are identifiable in the short-term, such as pain or reliable surrogate markers. Combining data from identical n-of-1 trials across a set of patients enables the statistical analysis controlling for patient fixed or random effects, covariates, centers, or sequence effects, see Figure below. These combined trials are often analyzed within a Bayesian context using shrinkage estimators that combine individual and group mean treatment effects to create a “posterior” individual mean treatment effect estimate which is a form of inverse variance-weighted average of the individual and group effects. Such trials are typically more expensive than standard RCTs on a per-patient basis, however, they require much smaller sample sizes, often less than 100 patients (due to the efficient individual-as-own-control design), and create individual treatment effect estimates that are not possible in a non-crossover design . For the individual patient, the treatment effect can be re-estimated after each time period, and the trial stopped at any point when the more effective treatment is identified with reasonable statistical certainty.

Example

A study involving 8 participants collected data across 30 days, in which 15 treatment days and 15 control days are randomly assigned within each participant. The treatment effect is represented as a binary variable (control day=0; treatment day=1). The outcome variable represents the response to the intervention within each of the 8 participants. Study employed a fixed-effects modeling. By creating N − 1 dummy-coded variables representing the N=8 participants, where the last (i=8) participant serves as the reference (i.e., as the model intercept). So, each dummy-coded variable represents the difference between each participant (i) and the 8th participant. Thus, all other patients' values will be relative to the values of the 8th (reference) subject. The overall differences across participants in fixed effects can be evaluated with multiple degree-of-freedom F-tests.

ID	Day	Tx	SelfEff	SelfEff25	WPSS	SocSuppt	PMss	PMss3	PhyAct
1	1	1	33	8	0.97	5.00	4.03	1.03	53
1	2	1	33	8	-0.17	3.87	4.03	1.03	73
1	3	0	33	8	0.81	4.84	4.03	1.03	23
1	4	0	33	8	-0.41	3.62	4.03	1.03	36
...	...	...	...	...	...	...	...	...	...

Complete data is available in the Appendix.

Data Summary

Intercept	Constant
Physical Activity	PhyAct
Intervention	Tx
WP Social Support	WPSS
PM Social Support (1-3)	PMss3
Self Efficacy	SelfEff25

rm(list=ls())
Nof1 <-read.table("https://umich.instructure.com/files/330385/download?download_frd=1&verifier=DwJUGSd6t24dvK7uYmzA2aDyzlmsohyaK6P7jK0Q", sep=",", header = TRUE)    # 02_Nof1_Data.csv
attach(Nof1)
head(Nof1)

	ID	Day	Tx	SelfEff	SelfEff25	WPSS	SocSuppt	PMss	PMss3	PhyAct
1	1	1	1	33	8	0.97	5.00	4.03	1.03	53
2	1	2	1	33	8	-0.17	3.87	4.03	1.03	73
3	1	3	0	33	8	0.81	4.84	4.03	1.03	23
4	1	4	0	33	8	-0.41	3.62	4.03	1.03	36
5	1	5	1	33	8	0.59	4.62	4.03	1.03	21
6	1	6	1	33	8	-1.16	2.87	4.03	1.03	0

df.1 = data.frame(PhyAct, Tx, WPSS, PMss3, SelfEff25) 

# library("lme4")

lm.1 = model.lmer <- lmer(PhyAct ~ Tx + SelfEff + Tx*SelfEff + (1|Day) + (1|ID) , data= df.1)
summary(lm.1)

Linear mixed model fit by REML ['lmerMod']
Formula: PhyAct ~ Tx + SelfEff + Tx * SelfEff + (1 | Day) + (1 | ID)
  Data: df.1

REML criterion at convergence: 8820

Scaled Residuals

Min

1Q

Median

3Q

Max

Random Effects

Groups	Name	Variance	Std.Dev.
Day	(Intercept)	0.0	0.00
ID	(Intercept)	601.5	24.53
Residual		969.0	31.13

Number of obs: 900, groups: Day, 30; ID, 30

Fixed Effects

Estimate	Std.	Error	t value
(Intercept)	38.3772	14.4738	2.651
Tx	4.0283	6.3745	0.632
SelfEff	0.5818	0.5942	0.979
Tx:SelfEff	0.9702	0.2617	3.708

Correlation of Fixed Effects

	(Intr)	Tx	SlfEff
Tx	-0.220
SelfEff	-0.946	0.208
Tx:SelfEff	0.208	-0.946	-0.220

# Model:  PhyAct = Tx + WPSS + PMss3 + Tx*WPSS + Tx*PMss3 + SelfEff25 + Tx*SelfEff25 + ε
lm.2 = lm(PhyAct ~ Tx + WPSS + PMss3 + Tx*WPSS + Tx*PMss3 + SelfEff25 + Tx*SelfEff25, df.1) 
summary(lm.2)

Call:
lm(formula = PhyAct ~ Tx + WPSS + PMss3 + Tx * WPSS + Tx * PMss3 + 
   SelfEff25 + Tx * SelfEff25, data = df.1)

Residuals

Min	1Q	Median	3Q	Max
-102.39	-28.24	-1.47	25.16	122.41

Coefficients

	Estimate	Std. Error	t value	t|)$
(Intercept)	52.0067	1.8080	28.764	< 2e-16 ***
Tx	27.7366	2.5569	10.848	< 2e-16 ***
WPSS	1.9631	2.4272	0.809	0.418853
PMss3	13.5110	2.7853	4.851	1.45e-06 ***
SelfEff25	0.6289	0.2205	2.852	0.004439 **
Tx:WPSS	9.9114	3.4320	2.888	0.003971 **
Tx:PMss3	8.8422	3.9390	2.245	0.025025 *
Tx:SelfEff25	1.0460	0.3118	3.354	0.000829 ***

[Using SAS (StudyI_Analyses.sas, StudyIIab_Analyses.sas)]

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	$Pr>F$
Tx	1	224	67.46	<.0001
ID	7	224	25.95	<.0001
Tx*ID	7	224	2.92	0.0060

Quantile Treatment Effect (QTE)

QTE employs quantile regression estimation (QRE) to examine the central tendency and statistical dispersion of the treatment effect in a population. These may not be revealed by the conventional mean estimation in RCTs. For instance, patients with different comorbidity scores may respond differently to a treatment. Quantile regression has the ability to reveal HTE according to the ranking of patients’ comorbidity scores or some other relevant covariate by which patients may be ranked. Therefore, in an attempt to inform patient-centered care, quantile regression provides more information on the distribution of the treatment effect than typical conditional mean treatment effect estimation. QTE characterizes the heterogeneous treatment effect on individuals and groups across various positions in the distributions of different outcomes of interest. This unique feature has given quantile regression analysis substantial attention and has been employed across a wide range of applications, particularly when evaluating the economic effects of welfare reform.

One caveat of applying QRE in clinical trials for examining HTE is that the QTE doesn’t demonstrate the treatment effect for a given patient. Instead, it focuses on the treatment effect among subjects within the qth quantile, such as those who are exactly at the top 10th percent in terms of blood pressure or a depression score for some covariate of interest, for example, comorbidity score. It is not uncommon for the qth quantiles to be two different sets of patients before and after the treatment. For this reason, we have to assume that these two groups of patients are homogeneous if they were in the same quantiles.

Income-Food Expenditure Example: Let’s examine the Engel data (N=235) on the relationship between food expenditure (foodexp) and household income (income). We can plot the data and then explore the superposition of the six fitted quantile regression lines.

install.packages("quantreg")
library(quantreg)
data(engel)
attach(engel)

head(engel)

	Income	Foodexp
1	420.1577	255.8394
2	541.4117	310.9587
3	901.1575	485.6800
4	639.0802	402.9974
5	750.8756	495.5608
6	945.7989	633.7978

summary(engel)

	Income	Foodexp
Min	377.1	242.3
1st Qu.	638.9	429.7
Median	884.0	582.5
Mean	982.5	624.2
3rd Qu.	1164.0	743.9
Max	4957.8	2032.7

Note: If Y be a real valued random variable with cumulative distribution function F_Y(y)=P(Y≤ y), then the τ-quantile of Y is given by

Q_Y(τ)=F_Y^-1(τ)=inf{ y:F_Y(y)≥τ}

where 0≤τ≤1.

# (1) Graphics
plot(income, foodexp, cex=.25, type="n", xlab="Household Income", ylab="Food Expenditure")
points(income, foodexp, cex=.5, col="blue")

# tau - the quantile(s) to be estimated, in the range from 0 to 1. An object "rq.process" and an object "rqs" 
# are returned containing the matrix of coefficient estimates at the specified quantiles.
abline( rq(foodexp ~ income, tau=.5), col="blue")  	# Quantile Regression Model

abline( lm(foodexp ~ income), lty=2, lwd=3, col="red") 	# linear model
taus <- c(0.05, 0.1, 0.25, 0.75, 0.90, 0.95)
colors <- rainbow(length(taus))

models <- vector(mode = "list", length = length(taus)) # define a vector of models to store QR for diff taus
model.names <- vector(mode = "list", length = length(taus)) # define a vector model names

for( i in 1:length(taus)){
modelsi <-  rq(foodexp ~ income, tau=taus[i]) 
var <- taus[i]
model.namesi <- paste("Model [", i , "]: tau=", var)
abline( modelsi, lwd=2, col= colorsi)
}
legend(3000, 1100, model.names, col= colors, pch= taus, bty='n', cex=.75)

# (2) Inference about quantile regression coefficients.  As an alternative to the rank-inversion confidence intervals, we can obtain a table of coefficients, standard errors, t-statistics, and p-values using the summary function:

summary(models3, se = "nid")

Call: rq(formula = foodexp ~ income, tau = taus[i])

tau: [1] 0.25

. . .

Nonparametric Regression Methods

. . .

Predictive risk models

. . .

Next see: Comparative Effectiveness Research (CER)

• Back to the Heterogeneity of Treatment Effects, Case-Studies of Comparative Effectiveness Research section

---

• SOCR Home page: http://www.socr.umich.edu

---

---

Translate this page:

(default)	Deutsch	Español	Français	Italiano	Português	日本語	България	الامارات العربية المتحدة	Suomi	इस भाषा में	Norge
한국어	中文	繁体中文	Русский	Nederlands	Ελληνικά	Hrvatska	Česká republika	Danmark	Polska	România	Sverige